Atara Resubmits Tabelecleucel BLA To FDA

Atara Biotherapeutics said partner Pierre Fabre Pharmaceuticals resubmitted the Biologics License Application for tabelecleucel to the FDA. The refiling advances the therapy toward a potential U.S. approval decision, representing a modestly positive regulatory catalyst for Atara.